What is the recommended treatment for Cushing disease?

Treatment of Cushing Disease

Transsphenoidal selective adenomectomy is the first-line treatment of choice for Cushing disease, performed by an experienced pituitary surgeon. 1, 2

Primary Treatment: Pituitary Surgery

Selective removal of the pituitary adenoma via transsphenoidal approach should be offered as initial therapy, as this maximizes preservation of normal pituitary tissue and achieves remission in 70-90% of cases when performed by experienced surgeons 1, 3.

Key Surgical Considerations:

• Surgeon experience is a critical predictor of success - seek centers with high-volume pituitary surgery expertise 1
• Post-operative remission correlates with: younger age, smaller adenoma size, absence of cavernous sinus/dural invasion, and morning serum cortisol <28 nmol/L (<1 μg/dL) after surgery 1
• Lifelong follow-up is essential - recurrence can occur up to 15 years after apparent cure 1

For Persistent or Recurrent Disease:

Consider repeat transsphenoidal surgery, which achieves early biochemical remission in 93% of pediatric patients and 50-70% of adults 1, 3

Second-Line Treatment: Radiotherapy

Offer focal radiotherapy for recurrent Cushing disease not amenable to curative surgery 1. Fractionated external beam radiotherapy (45 Gy in 25 fractions over 35 days) or stereotactic approaches achieve remission in approximately 85% of patients 1, 3.

Important Caveats:

• Radiotherapy has considerable latency period (typically 9-18 months for effect) 1
• Interim medical therapy is generally advisable while awaiting radiotherapy effects 3
• Risk of hypopituitarism is substantial with radiation therapy 3

Medical Therapy

Medical treatment plays a critical role when surgery fails, is contraindicated, or as bridging therapy. Surgery remains first-line; medical therapy is essential as second-line or adjunctive treatment 2.

Indications for Medical Therapy:

1. Pre-operative treatment in severe life-threatening hypercortisolism to reduce surgical risk 4, 5
2. Post-surgical failure or recurrence 2, 6
3. Bridging therapy while awaiting radiotherapy effects 6, 5
4. Primary therapy when surgery is contraindicated 2

Available Medical Options:

Adrenal Steroidogenesis Inhibitors (most commonly used):

• Osilodrostat: The most potent oral agent, FDA-approved for Cushing disease. Inhibits 11β-hydroxylase, rapidly decreases urinary free cortisol with sustained reductions, and improves glycemia, blood pressure, body weight, and quality of life 2

  • Monitor for: QT prolongation (requires ECG monitoring), adrenal insufficiency, hypokalemia, edema, hyperandrogenic symptoms 2
  • Use slower up-titration to minimize adverse effects 2

• Ketoconazole: Most commonly used historically (400-1,200 mg/day) due to availability and tolerability 1, 6

  • Critical warning: Hepatotoxicity requires liver function monitoring 1
  • Drug interaction alert: Potent CYP3A4 inhibitor - avoid simvastatin, lovastatin, atorvastatin; use pravastatin, rosuvastatin, or fluvastatin instead 7

• Metyrapone: Effective for rapid cortisol control (800-1,200 mg/day initially, maintenance 400-800 mg/day) 1

  • Pediatric concern: Prolonged use causes hyperandrogenism and advanced bone age in children 1

Pituitary-Directed Agents:

• Pasireotide: Somatostatin analog, FDA-approved, achieves remission in consistent subgroup of patients 6
• Cabergoline: Dopamine agonist, useful in selected cases 6

Glucocorticoid Receptor Blocker:

• Mifepristone: Highly effective for controlling clinical comorbidities, especially glucose intolerance; FDA-approved for Cushing syndrome with diabetes 6
  • Reduces HDL-C but improves glycemic control and blood pressure 7

Combination Therapy:

Consider combining different drug classes (e.g., ketoconazole + metyrapone) for severe cases or inadequate monotherapy response 5, 8

Bilateral Adrenalectomy

Reserve bilateral adrenalectomy only for severe refractory disease or life-threatening emergencies 1. This provides rapid, definitive cortisol control but requires:

• Lifelong adrenal hormone replacement 3
• High risk of Nelson syndrome (corticotroph tumor progression), especially in children 1

Common Pitfalls to Avoid:

1. Delaying treatment in severe hypercortisolism - use fast-acting steroidogenesis inhibitors or etomidate for life-threatening cases 4, 8
2. Inadequate post-operative monitoring - recurrence can occur years later; lifelong surveillance is mandatory 1
3. Drug interactions with ketoconazole - always check statin compatibility 7
4. Premature bilateral adrenalectomy - exhaust other options first given Nelson syndrome risk 1
5. Not using interim medical therapy after radiotherapy - the latency period requires cortisol control 3

Special Populations

In children and adolescents: Medical therapies should be confined to normalizing cortisol pre-operatively or while awaiting radiotherapy response, not as long-term therapy, due to effects on growth and puberty 1